Cantrixil

• CAT Number: I024009
• CAS Number: 2135511-22-5
• Molecular Formula: C24H24O6
• Molecular Weight: 408.44
• Purity: ≥95%
• Synonyms: (3R,4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H-chromen-7-ol
• InChI: InChI=1S/C24H24O6/c1-13-19(26)9-8-17-22(14-4-6-16(25)7-5-14)18(12-30-24(13)17)15-10-20(28-2)23(27)21(11-15)29-3/h4-11,18,22,25-27H,12H2,1-3H3/t18-,22-/m0/s1
• InChIKey: JFVVPUGGRUGRBJ-AVRDEDQJSA-N
• SMILES: CC1=C(C=CC2=C1OCC(C2C3=CC=C(C=C3)O)C4=CC(=C(C(=C4)OC)O)OC)O

Cantrixil (Cat No.: I024009) is a third-generation benzopyran-based investigational anticancer agent designed to target chemotherapy-resistant ovarian cancer stem cells. By inducing apoptosis and disrupting cancer stem cell survival pathways, Cantrixil has demonstrated the ability to overcome drug resistance and enhance the effectiveness of standard chemotherapeutics. It has been evaluated in clinical trials for recurrent ovarian cancer, showing potential to reduce tumor recurrence and progression. Cantrixil serves as a valuable tool in oncology research, particularly in studies of cancer stem cell biology.

Reference

[1]. Muhammad Wasif Saif, et al. Pharmacology and toxicology of the novel investigational agent Cantrixil (TRX-E-002-1). Cancer Chemother Pharmacol. 2017 Feb;79(2):303-314.
[Content Brief]

[2]. Ayesha B Alvero, et al. TRX-E-002-1 Induces c-Jun-Dependent Apoptosis in Ovarian Cancer Stem Cells and Prevents Recurrence In Vivo. Mol Cancer Ther. 2016 Jun;15(6):1279-90.
[Content Brief]